Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
58
STOK Quote, Financials, Valuation and Earnings
Last price:
$34.28
Seasonality move
:
28.03%
Day range:
$30.68 - $34.67
52-week range:
$5.35 - $38.69
Dividend yield:
0%
P/E ratio:
52.08x
P/S ratio:
9.75x
P/B ratio:
6.37x
Volume:
1.2M
Avg. volume:
686.7K
1-year change:
269.57%
Market cap:
$2B
Revenue:
$36.6M
EPS (TTM):
$0.66
Analysts' Opinion
-
Consensus RatingStoke Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 10 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $41.89, Stoke Therapeutics, Inc. has an estimated upside of 21.88% from its current price of $34.37.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $35.00 representing 100% downside risk from its current price of $34.37.
Fair Value
-
According to the consensus of 10 analysts, Stoke Therapeutics, Inc. has 21.88% upside to fair value with a price target of $41.89 per share.
STOK vs. S&P 500
-
Over the past 5 trading days, Stoke Therapeutics, Inc. has overperformed the S&P 500 by 6.27% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Stoke Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Stoke Therapeutics, Inc. has grown year-over-year revenues for 6 quarters straight. In the most recent quarter Stoke Therapeutics, Inc. reported revenues of $10.6M.
Earnings Growth
-
Stoke Therapeutics, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Stoke Therapeutics, Inc. reported earnings per share of -$0.65.
Enterprise value:
1.7B
EV / Invested capital:
--
Price / LTM sales:
9.75x
EV / EBIT:
63.23x
EV / Revenue:
8.36x
PEG ratio (5yr expected):
--
EV / Free cash flow:
32.84x
Price / Operating cash flow:
38.30x
Enterprise value / EBITDA:
54.72x
Gross Profit (TTM):
$201.4M
Return On Assets:
11.82%
Net Income Margin (TTM):
19.73%
Return On Equity:
13.95%
Return On Invested Capital:
13.73%
Operating Margin:
-405.3%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $9.2M | $16.7M | $205.6M | $4.9M | $10.6M | |
| Gross Profit | $4.6M | $12.2M | $201.4M | $3.8M | $9.6M | |
| Operating Income | -$112.4M | -$117.3M | $27.2M | -$30M | -$43.1M | |
| EBITDA | -$107.7M | -$112.8M | $31.4M | -$28.9M | -$42.1M | |
| Diluted EPS | -$2.43 | -$2.10 | $0.66 | -$0.47 | -$0.65 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $244.8M | $264.6M | $230M | $253.6M | $272.4M | |
| Total Assets | $253.8M | $277.6M | $239.9M | $293.3M | $360.3M | |
| Current Liabilities | $11.9M | $28.8M | $25.2M | $49.9M | $41.7M | |
| Total Liabilities | $16.3M | $73.5M | $66.9M | $61.2M | $52.2M | |
| Total Equity | $237.5M | $204.1M | $173M | $232.1M | $308.1M | |
| Total Debt | $3.9M | $3.3M | $819K | $3M | $1.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$82.8M | -$84.3M | $52.8M | -$21.6M | -$30.4M | |
| Cash From Investing | $113.7M | -$93.5M | -$124.9M | -$30M | $9.1M | |
| Cash From Financing | $45.7M | $137.9M | $5.6M | $8.2M | $3.1M | |
| Free Cash Flow | -$84.6M | -$84.7M | $52.4M | -$21.7M | -$30.5M | |
STOK
Sector
Market Cap
$2B
$25.2M
Price % of 52-Week High
88.83%
49.83%
Dividend Yield
0%
0%
Shareholder Yield
-0.42%
-1.77%
1-Year Price Total Return
269.57%
-21.9%
Beta (5-Year)
1.101
0.499
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$32.11
200-day SMA
Buy
Level
$22.30
Bollinger Bands (100)
Buy
Level
27.15 - 33.43
Chaikin Money Flow
Buy
Level
650.6K
20-day SMA
Buy
Level
$31.27
Relative Strength Index (RSI14)
Buy
Level
61.09
ADX Line
Buy
Level
6.45
Williams %R
Sell
Level
-5.6403
50-day SMA
Buy
Level
$31.69
MACD (12, 26)
Buy
Level
4.65
25-day Aroon Oscillator
Buy
Level
84
On Balance Volume
Neutral
Level
646.2K
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (5.6309)
Sell
CA Score
(Annual)
Level (-0.9634)
Sell
Beneish M-Score
(Annual)
Level (-1.1722)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (2.6939)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.
Stock Forecast FAQ
In the current month, STOK has received 10 Buy ratings 0 Hold ratings, and 0 Sell ratings. The STOK average analyst price target in the past 3 months is $41.89.
-
Where Will Stoke Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Stoke Therapeutics, Inc. share price will rise to $41.89 per share over the next 12 months.
-
What Do Analysts Say About Stoke Therapeutics, Inc.?
Analysts are divided on their view about Stoke Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Stoke Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $35.00.
-
What Is Stoke Therapeutics, Inc.'s Price Target?
The price target for Stoke Therapeutics, Inc. over the next 1-year time period is forecast to be $41.89 according to 10 Wall Street analysts, 10 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is STOK A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Stoke Therapeutics, Inc. is a Buy. 10 of 10 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of STOK?
You can purchase shares of Stoke Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Stoke Therapeutics, Inc. shares.
-
What Is The Stoke Therapeutics, Inc. Share Price Today?
Stoke Therapeutics, Inc. was last trading at $34.28 per share. This represents the most recent stock quote for Stoke Therapeutics, Inc.. Yesterday, Stoke Therapeutics, Inc. closed at $34.37 per share.
-
How To Buy Stoke Therapeutics, Inc. Stock Online?
In order to purchase Stoke Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get STOK Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
STOK
Sector
P/E ratio
52.08x
23.30x
PEG ratio
--
-0.01x
P/B ratio
6.37x
1.78x
Price / LTM sales
9.75x
1.55x
Growth Metrics
STOK
Sector
Revenue growth
117.25%
3.69%
Earnings growth
-39.48%
9.95%
Revenue (5-year growth)
--
6.38%
Earnings forecast
-$0.72
-$0.19
Profitability
STOK
Sector
Profitability FY 2024
$32.1M
$2.6M
Return on invested capital
13.73%
-33.25%
Return on assets
11.82%
-29.67%
Return on equity
13.95%
-38.66%
Earnings Date
Last Earnings Date
Nov
4
Next Earnings Date
Mar
24
Estimated Next Earnings Date
Feb
3
Balance Sheet
STOK
Sector
Total cash
$248.3M
$25.1M
Short term investments
$88.9M
$24M
Total assets
$271.6M
$72.5M
Long term debt
$1.9M
$2.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
23
CAR alert for Feb 20
Avis Budget Group, Inc. [CAR] is down 0.3% over the past day.
Buy
75
HYMC alert for Feb 20
Hycroft Mining Holding Corp. [HYMC] is down 2.47% over the past day.
Sell
1
EPAM alert for Feb 20
EPAM Systems, Inc. [EPAM] is down 0.11% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
